Reference : Immunogenicity of semisynthetic human insulin in man. Long-term comparison with porci...
Scientific journals : Article
Human health sciences : Endocrinology, metabolism & nutrition
Immunogenicity of semisynthetic human insulin in man. Long-term comparison with porcine monocomponent insulin.
Luyckx, A. S. [> > > >]
Daubresse, J. C. [> > > >]
Jaminet, C. [> > > >]
Scheen, André mailto [Université de Liège - ULiège > Département des sciences cliniques > Diabétologie, nutrition et maladie métaboliques - Médecine interne générale >]
Lefebvre, Pierre [Centre Hospitalier Universitaire de Liège - CHU > > Diabétologie,nutrition, maladies métaboliques >]
Acta Diabetologica Latina
Il Ponte
Yes (verified by ORBi)
[en] Adult ; Animals ; Antibodies/analysis ; Antibody Formation ; Diabetes Mellitus, Type 1/drug therapy/immunology/physiopathology ; Female ; Humans ; Insulin/chemical synthesis/immunology/therapeutic use ; Islets of Langerhans/physiopathology ; Male ; Middle Aged ; Prospective Studies ; Swine ; Time Factors
[en] The levels of circulating IgG-insulin antibodies were determined in two groups of diabetic patients before and at 3-month intervals after starting insulin treatment either with monocomponent porcine insulin (n = 17) or with human semisynthetic insulin (SH) (n = 16). Patients were followed during 15.1 +/- 1.0 and 19.9 +/- 1.1 months, respectively (m +/- SEM). In addition, the quality of metabolic control and residual B-cell function were evaluated in the group under treatment with SHI. The percentage of patients who remained antibody-free after 12-21 months of treatment was 67.75% in the human insulin-treated group and only 25-43% in the one receiving porcine insulin (p less than 0.01). Moreover, insulin antibody titers, when present, were usually lower in subjects treated with human insulin. In SHI-treated patients: metabolic control was excellent during the first months of treatment as evidenced by values of mean daily blood glucose (7.3 +/- 0.6 mmol/l), M-index according to Schlichtkrull (7.4 +/- 2.4) and Hb1c (6.8 +/- 0.6%); residual B-cell function, evaluated at 3-month intervals by a circadian profile of plasma C-peptide did not decrease throughout the study; and a significant deterioration of blood glucose control occurred after 18 months of treatment, which might have been due to a less intensive supervision of the patients by the physicians and/or less careful attention by the patients themselves. This observation confirms the need for a continuous education of the patients regardless of the type of insulin used.

There is no file associated with this reference.

Bookmark and Share SFX Query

All documents in ORBi are protected by a user license.